1. Alan M. Krensky, Jamil R. Azzi, and David A. Hafler. Immunosuppressants and Tolerogens. Goodman & Gilman’s: The Pharmacological basics of Therapeutics. 13th Edition. New York McGraw Hill Medical 2018. Page – 638-653.
2. David N. Franz, Elena Belousova, Steven Sparagana, E. Martina Bebin, Michael D. Frost, Rachel Kuperman, et.al. Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Results from the EXIST-1 Study. Journal of Plos one. June 2018. [Accessed on 11th June 2022] https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0158476
3. Katarzyna Bobeff, Karolina Krajewska, Dobromila Baranska, Katarzyna Kotulska, Sergiusz Jozwiak, Wojciech Mlynarski and Joanna Trelinska. Maintenance Therapy With Everolimus for Subependymal Giant Cell Astrocytoma in Patients With Tuberous Sclerosis –Results From the EMINENTS Study. Journal of Frontiers in Neurology. April 2021. [Accessed on 11th June 2022] https://www.frontiersin.org/articles/10.3389/fneur.2021.581102/full
4. Peri M, Fazio N. Clinical Evaluation of Everolimus in the Treatment of Neuroendocrine Tumor of the Lung: Patient Selection and Special Considerations. Systematic and Critical Review of the Literature. Journal of lung cancer: targets and therapy. June 2020. [Accessed on 11th June 2022] https://www.dovepress.com/clinical-evaluation-of-everolimus-in-the-treatment-of-neuroendocrine-t-peer-reviewed-fulltext-article-LCTT
5. Ajay Dhakal, Roby Antony Thomas, Ellis G Levine, Adam Brufsky, Kazuaki Takabe, Matthew G Hanna, et.al. Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib. SAGE Journals (July 2020). [Accessed on 11th June 2022] https://journals.sagepub.com/doi/full/10.1177/1178223420944864
6. Novartis Pharmaceuticals UK Limited. Electronic Medicines Compendium (EMC). [Revised in January 2022] [Accessed 11th June 2022] https://www.medicines.org.uk/emc/files/pil.6658.pdf
7. Accord Healthcare Limited. Electronic Medicines Compendium (EMC). [Revised in February 2022] [Accessed 11th June 2022] https://www.medicines.org.uk/emc/files/pil.11084.pdf
8. Novartis Pharmaceuticals Corporation. US Food and Drug Administration. [Revised in July 2012] [Accessed on 11th June 2022] https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022334s016lbl.pdf